Cite

HARVARD Citation

    Sprague, S. et al. (2015). Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease. Clinical investigation. pp. 9-21. [Online]. 
  
Back to record